January 13, 2023 01:28 PM EST

EMA developing physician guidance for potential liver damage after taking Zolgensma

Katherine Lewin

News Reporter

The European Medicines Agency is working on new advice for healthcare providers treating patients with Zolgensma, five months after two child patient …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

EMA developing physician guidance for potential liver damage after taking Zolgensma

Katherine Lewin

News Reporter

Sign up to read this article for free.

Exclusive: Two Vida Ventures co-founders exit the VC firm

Cases of severe RSV in two Moderna vaccine candidates' trials raise questions about future

Early data on BTK degraders suggest promise of next-gen approach

Walgreens in talks to sell to private equity — report

UniQure stock doubles on FDA 'alignment' over accelerated approval for Huntington's drug

The key to faster, more impactful research? Put patients in the driver’s seat

EMA de­vel­op­ing physi­cian guid­ance for po­ten­tial liv­er dam­age af­ter tak­ing Zol­gens­ma

Katherine Lewin

News Reporter

Sign up to read this article for free.

Ex­clu­sive: Two Vi­da Ven­tures co-founders ex­it the VC firm

Cas­es of se­vere RSV in two Mod­er­na vac­cine can­di­dates' tri­als raise ques­tions about fu­ture

Ear­ly da­ta on BTK de­graders sug­gest promise of next-gen ap­proach

Wal­greens in talks to sell to pri­vate eq­ui­ty — re­port

UniQure stock dou­bles on FDA 'align­men­t' over ac­cel­er­at­ed ap­proval for Hunt­ing­ton's drug

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

EMA developing physician guidance for potential liver damage after taking Zolgensma

Exclusive: Two Vida Ventures co-founders exit the VC firm

Cases of severe RSV in two Moderna vaccine candidates' trials raise questions about future

Early data on BTK degraders suggest promise of next-gen approach

Walgreens in talks to sell to private equity — report

UniQure stock doubles on FDA 'alignment' over accelerated approval for Huntington's drug

The key to faster, more impactful research? Put patients in the driver’s seat